Employee Benefit Plans (Details)
|
12 Months Ended |
|
Dec. 31, 2016
USD ($)
$ / shares
shares
|
Dec. 31, 2015
USD ($)
$ / shares
shares
|
Dec. 31, 2014
USD ($)
$ / shares
shares
|
| Stock based compensation by job function [Line Items] |
|
|
|
|
|
|
| Stock-Based Compensation Expenses | $ |
|
$ 128,090,000
|
|
$ 130,577,000
|
|
$ 144,842,000
|
| Federal income tax (expense) / benefit recognized from stock-based compensation | $ |
|
$ 29,000,000
|
|
$ 26,000,000
|
|
$ 99,000,000
|
| Share-Based Compensation Arrangement By Share-Based Payment Award [Abstract] |
|
|
|
|
|
|
| Common Shares Available for Grant |
|
21,500,000
|
|
|
|
|
| Restricted Stock And Restricted Stock Units [Member] |
|
|
|
|
|
|
| Stock option and SAR Rollforward [Abstract] |
|
|
|
|
|
|
| Outstanding at January 1 (in shares) |
|
4,908,000
|
[1] |
5,394,000
|
[1] |
7,358,000
|
| Granted (in shares) |
|
853,000
|
|
1,044,000
|
|
1,132,000
|
| Exercised (in shares) |
[2] |
(1,465,000)
|
|
(1,331,000)
|
|
(2,761,000)
|
| Forfeited (in shares) |
|
(334,000)
|
|
(199,000)
|
|
(335,000)
|
| Outstanding at December 31 (in shares) |
[1] |
3,962,000
|
|
4,908,000
|
|
5,394,000
|
| Share-Based Compensation Arrangement By Share-Based Payment Award [Abstract] |
|
|
|
|
|
|
| Outstanding at January 1 (in dollars per share) | $ / shares |
|
$ 70.35
|
[1] |
$ 64.39
|
[1] |
$ 49.54
|
| Granted (in dollars per share) | $ / shares |
|
88.01
|
|
77.94
|
|
98.72
|
| Exercised (in dollars per share) | $ / shares |
[2] |
53.95
|
|
51.52
|
|
105.24
|
| Forfeited (in dollars per share) | $ / shares |
|
77.29
|
|
74.56
|
|
62.55
|
| Outstanding at December 31 (in dollars per share) | $ / shares |
[1] |
$ 79.63
|
|
$ 70.35
|
|
$ 64.39
|
| Weighted average period over which unrecognized compensation expense will be recognized |
|
2 years 6 months
|
|
|
|
|
| Unrecognized compensation expense | $ |
|
$ 153,000,000
|
|
|
|
|
| Share Based Compensation Arrangement By Restricted Stock And Restricted Stock Units Compensation Cost | $ |
|
$ 60,000,000
|
|
$ 69,000,000
|
|
$ 74,000,000
|
| Weighted Average Grant Fair Value [Abstract] |
|
|
|
|
|
|
| Maximum vest period from the date of grant |
|
5 years
|
|
|
|
|
| Stock Options And Sars [Member] |
|
|
|
|
|
|
| Stock based compensation by job function [Line Items] |
|
|
|
|
|
|
| Maximum term of stock options and SARs granted |
|
7 years
|
|
|
|
|
| Stock-based compensation expense related to stock options, SAR and ESPP grants | $ |
|
$ 57,000,000
|
|
$ 56,000,000
|
|
$ 62,000,000
|
| Weighted Average Fair Value And Valuation Assumptions Used To Value Stock-Based Compensation [Abstract] |
|
|
|
|
|
|
| Weighted Average Fair Value of Grants | $ / shares |
|
$ 25.78
|
|
$ 21.88
|
|
$ 30.75
|
| Expected Volatility (in hundredths) |
|
31.54%
|
|
38.03%
|
|
35.28%
|
| Risk-Free Interest Rate (in hundredths) |
|
0.78%
|
|
0.83%
|
|
0.95%
|
| Dividend Yield (in hundredths) |
|
0.76%
|
|
0.85%
|
|
0.61%
|
| Expected Life (in years) |
|
5 years 4 months 24 days
|
|
5 years 3 months 18 days
|
|
5 years 2 months 12 days
|
| Stock option and SAR Rollforward [Abstract] |
|
|
|
|
|
|
| Outstanding at January 1 (in shares) |
|
10,744,000
|
|
10,493,000
|
|
10,452,000
|
| Granted (in shares) |
|
1,855,000
|
|
2,037,000
|
|
2,146,000
|
| Exercised (in shares) |
[3] |
(2,376,000)
|
|
(1,518,000)
|
|
(1,718,000)
|
| Forfeited (in shares) |
|
(373,000)
|
|
(268,000)
|
|
(387,000)
|
| Outstanding at December 31 (in shares) |
|
9,850,000
|
|
10,744,000
|
|
10,493,000
|
| Share-Based Compensation Arrangement By Share-Based Payment Award [Abstract] |
|
|
|
|
|
|
| Outstanding at January 1 (in dollars per share) | $ / shares |
|
$ 67.98
|
|
$ 64.96
|
|
$ 54.43
|
| Granted (in dollars per share) | $ / shares |
|
94.82
|
|
69.99
|
|
101.55
|
| Exercised (in dollars per share) | $ / shares |
[3] |
54.56
|
|
47.64
|
|
45.68
|
| Forfeited (in dollars per share) | $ / shares |
|
87.38
|
|
80.31
|
|
68.95
|
| Outstanding at December 31 (in dollars per share) | $ / shares |
|
$ 75.53
|
|
$ 67.98
|
|
$ 64.96
|
| Stock Options/SARs Exercisable at December 31 (in shares) |
|
5,613,000
|
|
5,993,000
|
|
5,287,000
|
| Stock Options/SARs Exercisable at December 31 (in dollars per share) | $ / shares |
|
$ 66.48
|
|
$ 57.96
|
|
$ 49.40
|
| Stock options/SARs vested or expected to vest (in shares) |
|
9,500,000
|
|
|
|
|
| Weighted average grant price for stock options/SARs vested or expected to vest (per share) | $ / shares |
|
$ 75.12
|
|
|
|
|
| Intrinsic value of stock options/SARs vested or expected to vest | $ |
|
$ 249,000,000
|
|
|
|
|
| Weighted average period over which unrecognized compensation expense will be recognized |
|
2 years 9 months 18 days
|
|
|
|
|
| Unrecognized compensation expense | $ |
|
$ 95,000,000
|
|
|
|
|
| Weighted Average Grant Fair Value [Abstract] |
|
|
|
|
|
|
| Maximum vest period from the date of grant |
|
4 years
|
|
|
|
|
| Summary Information By Grant Price Range For Stock Options And SARs Outstanding And Exercisable At End Of Period [Line Items] |
|
|
|
|
|
|
| Stock Options and SARs Outstanding |
|
9,850,000
|
|
|
|
|
| Weighted Average Remaining Life for Outstanding Options and SARs |
|
4 years
|
|
|
|
|
| Weighted Average Grant Price For Outstanding Options and SARs | $ / shares |
|
$ 75.53
|
|
|
|
|
| Aggregate Intrinsic Value For Outstanding Options and SARs | $ |
[4] |
$ 253,400
|
|
|
|
|
| Stock Options and SARs Exercisable |
|
5,613,000
|
|
|
|
|
| Weighted Average Remaining Life For Exercisable Units |
|
3 years
|
|
|
|
|
| Weighted Average Grant Price For Exercisable Options and SARs | $ / shares |
|
$ 66.48
|
|
|
|
|
| Aggregate Intrinsic Value For Exercisable Units | $ |
[4] |
$ 195,186
|
|
|
|
|
| Espp [Member] |
|
|
|
|
|
|
| Stock based compensation by job function [Line Items] |
|
|
|
|
|
|
| Maximum Percentage Of Employee Pay Eligible For Contribution To Espp Percentage |
|
10.00%
|
|
|
|
|
| Percentage of fair market value at which employees may purchase company stock via the ESPP |
|
85.00%
|
|
|
|
|
| Weighted Average Fair Value And Valuation Assumptions Used To Value Stock-Based Compensation [Abstract] |
|
|
|
|
|
|
| Weighted Average Fair Value of Grants | $ / shares |
|
$ 19.21
|
|
$ 21.21
|
|
$ 21.65
|
| Expected Volatility (in hundredths) |
|
36.55%
|
|
32.08%
|
|
25.03%
|
| Risk-Free Interest Rate (in hundredths) |
|
0.44%
|
|
0.12%
|
|
0.08%
|
| Dividend Yield (in hundredths) |
|
0.82%
|
|
0.73%
|
|
0.46%
|
| Expected Life (in years) |
|
6 months
|
|
6 months
|
|
6 months
|
| Share-Based Compensation Arrangement By Share-Based Payment Award [Abstract] |
|
|
|
|
|
|
| Common Shares Available for Grant |
|
356,000
|
|
|
|
|
| Approximate Number of Participants |
|
1,746
|
|
1,963
|
|
1,991
|
| Shares Purchased |
|
212,000
|
|
225,000
|
|
202,000
|
| Aggregate Purchase Price | $ |
|
$ 13,787,000
|
|
$ 15,045,000
|
|
$ 14,927,000
|
| Performance Units and Performance Stock [Member] |
|
|
|
|
|
|
| Weighted Average Fair Value And Valuation Assumptions Used To Value Stock-Based Compensation [Abstract] |
|
|
|
|
|
|
| Weighted Average Fair Value of Grants | $ / shares |
|
$ 119.10
|
|
$ 80.64
|
|
$ 119.27
|
| Expected Volatility (in hundredths) |
|
32.48%
|
|
29.35%
|
|
32.18%
|
| Risk-Free Interest Rate (in hundredths) |
|
1.15%
|
|
1.07%
|
|
1.18%
|
| Share-Based Compensation Arrangement By Share-Based Payment Award [Abstract] |
|
|
|
|
|
|
| Weighted average period over which unrecognized compensation expense will be recognized |
|
3 years
|
|
|
|
|
| Unrecognized compensation expense | $ |
|
$ 10,000,000
|
|
|
|
|
| Number of Shares and Units [Roll Forward] |
|
|
|
|
|
|
| Outstanding at January 1 (in shares) |
|
405,000
|
|
|
|
|
| Granted (in shares) |
|
131,750
|
|
|
|
|
| Released (in shares) |
|
(134,016)
|
|
|
|
|
| Outstanding at December 31 [1] (in shares) |
|
545,290
|
|
405,000
|
|
|
| Weighted Average Grant Fair Value [Abstract] |
|
|
|
|
|
|
| Intrinsic value of stock based compensation | $ |
|
$ 9,700,000
|
|
|
|
|
| Performance Units and Performance Stock [Abstract] |
|
|
|
|
|
|
| Minimum Performance Multiple at the Completion Performance Period |
|
0.00%
|
|
|
|
|
| Maximum Performance Multiple at the Completion Performance Period |
|
200.00%
|
|
|
|
|
| Minimum Performance Units and Stock Allowed to be Outstanding |
|
151,096
|
|
|
|
|
| Maximum Performance Units and Stock Allowed to be Outstanding |
|
939,484
|
|
|
|
|
| Share Based Compensation Arrangement By Performance Units and Stock Compensation Cost | $ |
|
$ 11,000,000
|
|
$ 5,000,000
|
|
$ 9,000,000
|
| Term of Zero-Coupon Risk-Free Interest Rate Derived from the Treasury Constant Maturities Yield Curve |
|
3 years 3 months
|
|
|
|
|
| Additional Performance Awards Granted |
|
118,834
|
|
142,556
|
|
|
| Summary Information By Grant Price Range For Stock Options And SARs Outstanding And Exercisable At End Of Period [Line Items] |
|
|
|
|
|
|
| Aggregate Intrinsic Value For Outstanding Options and SARs | $ |
|
$ 55,100,000
|
|
|
|
|
| Lease And Well [Member] |
|
|
|
|
|
|
| Stock based compensation by job function [Line Items] |
|
|
|
|
|
|
| Stock-Based Compensation Expenses | $ |
|
38,000,000
|
|
$ 44,000,000
|
|
41,000,000
|
| Gathering And Processing Costs [Member] |
|
|
|
|
|
|
| Stock based compensation by job function [Line Items] |
|
|
|
|
|
|
| Stock-Based Compensation Expenses | $ |
|
1,000,000
|
|
1,000,000
|
|
1,000,000
|
| Exploration Costs [Member] |
|
|
|
|
|
|
| Stock based compensation by job function [Line Items] |
|
|
|
|
|
|
| Stock-Based Compensation Expenses | $ |
|
21,000,000
|
|
26,000,000
|
|
27,000,000
|
| General And Administrative [Member] |
|
|
|
|
|
|
| Stock based compensation by job function [Line Items] |
|
|
|
|
|
|
| Stock-Based Compensation Expenses | $ |
|
$ 68,000,000
|
|
60,000,000
|
|
76,000,000
|
| $ 34.00 to $ 55.99 | Stock Options And Sars [Member] |
|
|
|
|
|
|
| Summary Information By Grant Price Range For Stock Options And SARs Outstanding And Exercisable At End Of Period [Line Items] |
|
|
|
|
|
|
| Stock Options and SARs Outstanding |
|
1,906,000
|
|
|
|
|
| Weighted Average Remaining Life for Outstanding Options and SARs |
|
1 year
|
|
|
|
|
| Weighted Average Grant Price For Outstanding Options and SARs | $ / shares |
|
$ 43.68
|
|
|
|
|
| Stock Options and SARs Exercisable |
|
1,906,000
|
|
|
|
|
| Weighted Average Remaining Life For Exercisable Units |
|
1 year
|
|
|
|
|
| Weighted Average Grant Price For Exercisable Options and SARs | $ / shares |
|
$ 43.68
|
|
|
|
|
| 56.00 to 69.99 | Stock Options And Sars [Member] |
|
|
|
|
|
|
| Summary Information By Grant Price Range For Stock Options And SARs Outstanding And Exercisable At End Of Period [Line Items] |
|
|
|
|
|
|
| Stock Options and SARs Outstanding |
|
2,922,000
|
|
|
|
|
| Weighted Average Remaining Life for Outstanding Options and SARs |
|
4 years
|
|
|
|
|
| Weighted Average Grant Price For Outstanding Options and SARs | $ / shares |
|
$ 64.12
|
|
|
|
|
| Stock Options and SARs Exercisable |
|
1,654,000
|
|
|
|
|
| Weighted Average Remaining Life For Exercisable Units |
|
3 years
|
|
|
|
|
| Weighted Average Grant Price For Exercisable Options and SARs | $ / shares |
|
$ 60.09
|
|
|
|
|
| 70.00 to 94.99 | Stock Options And Sars [Member] |
|
|
|
|
|
|
| Summary Information By Grant Price Range For Stock Options And SARs Outstanding And Exercisable At End Of Period [Line Items] |
|
|
|
|
|
|
| Stock Options and SARs Outstanding |
|
1,526,000
|
|
|
|
|
| Weighted Average Remaining Life for Outstanding Options and SARs |
|
3 years
|
|
|
|
|
| Weighted Average Grant Price For Outstanding Options and SARs | $ / shares |
|
$ 84.62
|
|
|
|
|
| Stock Options and SARs Exercisable |
|
1,072,000
|
|
|
|
|
| Weighted Average Remaining Life For Exercisable Units |
|
3 years
|
|
|
|
|
| Weighted Average Grant Price For Exercisable Options and SARs | $ / shares |
|
$ 84.49
|
|
|
|
|
| 95.00 to 99.99 | Stock Options And Sars [Member] |
|
|
|
|
|
|
| Summary Information By Grant Price Range For Stock Options And SARs Outstanding And Exercisable At End Of Period [Line Items] |
|
|
|
|
|
|
| Stock Options and SARs Outstanding |
|
1,794,000
|
|
|
|
|
| Weighted Average Remaining Life for Outstanding Options and SARs |
|
7 years
|
|
|
|
|
| Weighted Average Grant Price For Outstanding Options and SARs | $ / shares |
|
$ 95.10
|
|
|
|
|
| Stock Options and SARs Exercisable |
|
23,000
|
|
|
|
|
| Weighted Average Remaining Life For Exercisable Units |
|
3 years
|
|
|
|
|
| Weighted Average Grant Price For Exercisable Options and SARs | $ / shares |
|
$ 97.31
|
|
|
|
|
| 100.00 to 116.99 | Stock Options And Sars [Member] |
|
|
|
|
|
|
| Summary Information By Grant Price Range For Stock Options And SARs Outstanding And Exercisable At End Of Period [Line Items] |
|
|
|
|
|
|
| Stock Options and SARs Outstanding |
|
1,702,000
|
|
|
|
|
| Weighted Average Remaining Life for Outstanding Options and SARs |
|
4 years
|
|
|
|
|
| Weighted Average Grant Price For Outstanding Options and SARs | $ / shares |
|
$ 102.02
|
|
|
|
|
| Stock Options and SARs Exercisable |
|
958,000
|
|
|
|
|
| Weighted Average Remaining Life For Exercisable Units |
|
4 years
|
|
|
|
|
| Weighted Average Grant Price For Exercisable Options and SARs | $ / shares |
|
$ 102.00
|
|
|
|
|
| Pension Plans [Member] |
|
|
|
|
|
|
| Defined Benefit and Defined Contribution Plan Disclosure [Line Items] |
|
|
|
|
|
|
| Total pension plan costs | $ |
|
$ 34,000,000
|
|
36,000,000
|
|
41,000,000
|
| Company contributions to foreign pension plans | $ |
|
1,000,000
|
|
1,000,000
|
|
$ 5,000,000
|
| Benefit obligation | $ |
|
8,000,000
|
|
9,000,000
|
|
|
| Fair value of foreign pension plan assets | $ |
|
7,000,000
|
|
7,000,000
|
|
|
| Accrued benefit cost | $ |
|
$ (300,000)
|
|
$ (200,000)
|
|
|
|
|